[go: up one dir, main page]

WO2013134353A8 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor - Google Patents

Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor Download PDF

Info

Publication number
WO2013134353A8
WO2013134353A8 PCT/US2013/029304 US2013029304W WO2013134353A8 WO 2013134353 A8 WO2013134353 A8 WO 2013134353A8 US 2013029304 W US2013029304 W US 2013029304W WO 2013134353 A8 WO2013134353 A8 WO 2013134353A8
Authority
WO
WIPO (PCT)
Prior art keywords
fused bicyclic
fak inhibitor
diaminopyrimidine derivative
alk
dual alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/029304
Other languages
French (fr)
Other versions
WO2013134353A1 (en
Inventor
Martin J. Jacobs
Gregory R. Ott
Shawn P. Allwein
Laurent Courvoisier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013134353(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to RS20160238A priority Critical patent/RS54689B1/en
Priority to SG11201405371PA priority patent/SG11201405371PA/en
Priority to HRP20160387TT priority patent/HRP20160387T1/en
Priority to EA201491641A priority patent/EA025859B1/en
Priority to EP13710258.8A priority patent/EP2822939B1/en
Priority to MEP-2016-68A priority patent/ME02460B/en
Priority to HK15105852.9A priority patent/HK1205119B/en
Priority to NZ630251A priority patent/NZ630251A/en
Priority to CN201380012764.6A priority patent/CN104159894B/en
Priority to MX2017006206A priority patent/MX372740B/en
Priority to PL13710258T priority patent/PL2822939T3/en
Priority to KR1020147027590A priority patent/KR102068374B1/en
Priority to JP2014561069A priority patent/JP6016953B2/en
Priority to UAA201410832A priority patent/UA115052C2/en
Priority to AU2013229995A priority patent/AU2013229995B2/en
Priority to CA2865420A priority patent/CA2865420C/en
Application filed by Cephalon LLC filed Critical Cephalon LLC
Priority to ES13710258T priority patent/ES2570976T3/en
Priority to SI201330151T priority patent/SI2822939T1/en
Priority to DK13710258.8T priority patent/DK2822939T3/en
Priority to MX2014010613A priority patent/MX347772B/en
Publication of WO2013134353A1 publication Critical patent/WO2013134353A1/en
Publication of WO2013134353A8 publication Critical patent/WO2013134353A8/en
Priority to IL234239A priority patent/IL234239A/en
Priority to ZA2014/06147A priority patent/ZA201406147B/en
Priority to US14/474,928 priority patent/US9132128B2/en
Priority to CL2014002353A priority patent/CL2014002353A1/en
Priority to PH12014501979A priority patent/PH12014501979A1/en
Anticipated expiration legal-status Critical
Priority to US14/824,750 priority patent/US9339502B2/en
Priority to US15/146,164 priority patent/US9623026B2/en
Priority to SM201600134T priority patent/SMT201600134B/en
Priority to US15/451,960 priority patent/US10111872B2/en
Priority to IL252364A priority patent/IL252364B/en
Priority to US16/172,368 priority patent/US10632119B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
PCT/US2013/029304 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor Ceased WO2013134353A1 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SI201330151T SI2822939T1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
SG11201405371PA SG11201405371PA (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
HRP20160387TT HRP20160387T1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EA201491641A EA025859B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EP13710258.8A EP2822939B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
MEP-2016-68A ME02460B (en) 2012-03-06 2013-03-06 CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ALK AND FAK HEMMER
HK15105852.9A HK1205119B (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
NZ630251A NZ630251A (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
CN201380012764.6A CN104159894B (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivatives as dual inhibitors of ALK and FAK
MX2017006206A MX372740B (en) 2012-03-06 2013-03-06 FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR.
PL13710258T PL2822939T3 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR1020147027590A KR102068374B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP2014561069A JP6016953B2 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivatives as dual ALK and FAK inhibitors
UAA201410832A UA115052C2 (en) 2012-03-06 2013-03-06 CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK- AND FAK INHIBITOR
AU2013229995A AU2013229995B2 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
CA2865420A CA2865420C (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
ES13710258T ES2570976T3 (en) 2012-03-06 2013-03-06 Condensed bicyclic 2,4-diaminopyrimidine derivative as dual inhibitor of ALK and FAK
RS20160238A RS54689B1 (en) 2012-03-06 2013-03-06 CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR
MX2014010613A MX347772B (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor.
DK13710258.8T DK2822939T3 (en) 2012-03-06 2013-03-06 CONDENSED BICYCLEIC 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS DUAL ALK AND FAK INHIBITORS
ZA2014/06147A ZA201406147B (en) 2012-03-06 2014-08-21 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
IL234239A IL234239A (en) 2012-03-06 2014-08-21 Fused bicyclic 2, 4 - diaminopyrimidine derivatives as a dual alk and fak inhibitor
US14/474,928 US9132128B2 (en) 2012-03-06 2014-09-02 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
CL2014002353A CL2014002353A1 (en) 2012-03-06 2014-09-05 Compound 2 - [[5-chloro-2 - [[(6s) -6- [4- (2-hydroxyethyl) piperazin-1-yl] -1-methoxy-6,7,8,9-tetrahydro-5h- benzo [7] anulen-2-yl] amino] pyrimidin-4-yl] amino] -n-methyl-benzamide, dual alk and fak inhibitor; compound salts; pharmaceutical composition; and method of treatment of gliobalstoma, prostate cancer and breast cancer, among others.
PH12014501979A PH12014501979A1 (en) 2012-03-06 2014-09-05 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
US14/824,750 US9339502B2 (en) 2012-03-06 2015-08-12 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
US15/146,164 US9623026B2 (en) 2012-03-06 2016-05-04 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
SM201600134T SMT201600134B (en) 2012-03-06 2016-05-10 2, 4-DIAMMINOPYRIMIDINE MOLTED BICYCLIC DERIVATIVE AS A DOUBLE INHIBITOR OF ALK AND FAK.
US15/451,960 US10111872B2 (en) 2012-03-06 2017-03-07 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
IL252364A IL252364B (en) 2012-03-06 2017-05-18 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
US16/172,368 US10632119B2 (en) 2012-03-06 2018-10-26 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
US61/607,305 2012-03-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/474,928 Continuation US9132128B2 (en) 2012-03-06 2014-09-02 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

Publications (2)

Publication Number Publication Date
WO2013134353A1 WO2013134353A1 (en) 2013-09-12
WO2013134353A8 true WO2013134353A8 (en) 2014-06-19

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/029304 Ceased WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Country Status (28)

Country Link
US (5) US9132128B2 (en)
EP (2) EP3056494B1 (en)
JP (2) JP6016953B2 (en)
KR (1) KR102068374B1 (en)
CN (2) CN104159894B (en)
AU (1) AU2013229995B2 (en)
CA (1) CA2865420C (en)
CL (1) CL2014002353A1 (en)
CY (1) CY1117565T1 (en)
DK (1) DK2822939T3 (en)
EA (2) EA025859B1 (en)
ES (2) ES2570976T3 (en)
HR (1) HRP20160387T1 (en)
HU (1) HUE027976T2 (en)
IL (2) IL234239A (en)
ME (1) ME02460B (en)
MX (2) MX347772B (en)
MY (1) MY177290A (en)
NZ (1) NZ630251A (en)
PH (1) PH12014501979A1 (en)
PL (1) PL2822939T3 (en)
RS (1) RS54689B1 (en)
SG (2) SG10201507865QA (en)
SI (1) SI2822939T1 (en)
SM (1) SMT201600134B (en)
UA (1) UA115052C2 (en)
WO (1) WO2013134353A1 (en)
ZA (1) ZA201406147B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115052C2 (en) * 2012-03-06 2017-09-11 Сефалон, Інк. CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK- AND FAK INHIBITOR
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
MX2021001398A (en) 2018-08-07 2021-08-16 In3Bio Ltd Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors.
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4607879B2 (en) 2003-08-15 2011-01-05 ノバルティス アーゲー 2,4-Pyrimidinediamine useful for the treatment of neoplastic diseases, inflammation and immune disorders
PL1713806T3 (en) * 2004-02-14 2013-09-30 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5512274B2 (en) * 2006-10-23 2014-06-04 セファロン、インク． Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK inhibitors and c-MET inhibitors
RS53588B1 (en) * 2006-12-08 2015-02-27 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
JP4782239B2 (en) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク Sulfonylamide derivatives for the treatment of abnormal cell proliferation
HUE046402T2 (en) * 2009-06-10 2020-03-30 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
UA115052C2 (en) * 2012-03-06 2017-09-11 Сефалон, Інк. CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK- AND FAK INHIBITOR
KR101446742B1 (en) * 2012-08-10 2014-10-01 한국화학연구원 N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
AU2013229995B2 (en) 2017-04-13
EP2822939A1 (en) 2015-01-14
EA201691574A1 (en) 2017-03-31
CN106166155A (en) 2016-11-30
CN106166155B (en) 2019-01-18
HK1205119A1 (en) 2015-12-11
SG11201405371PA (en) 2014-09-26
EA025859B1 (en) 2017-02-28
ES2570976T3 (en) 2016-05-23
CA2865420A1 (en) 2013-09-12
CL2014002353A1 (en) 2015-01-09
SG10201507865QA (en) 2015-10-29
RS54689B1 (en) 2016-08-31
US10111872B2 (en) 2018-10-30
IL234239A (en) 2017-06-29
EA201491641A1 (en) 2015-04-30
CY1117565T1 (en) 2017-04-26
CN104159894A (en) 2014-11-19
US20190328735A1 (en) 2019-10-31
MY177290A (en) 2020-09-10
HRP20160387T1 (en) 2016-05-20
KR102068374B1 (en) 2020-01-20
PH12014501979B1 (en) 2014-11-24
SMT201600134B (en) 2016-07-01
US10632119B2 (en) 2020-04-28
PH12014501979A1 (en) 2014-11-24
EP2822939B1 (en) 2016-02-17
AU2013229995A1 (en) 2014-09-25
MX347772B (en) 2017-05-12
US9339502B2 (en) 2016-05-17
PL2822939T3 (en) 2016-08-31
HUE027976T2 (en) 2016-11-28
CN104159894B (en) 2016-09-07
CA2865420C (en) 2020-06-02
US20170173017A1 (en) 2017-06-22
MX372740B (en) 2020-05-04
EP3056494B1 (en) 2018-05-02
KR20140138247A (en) 2014-12-03
UA115052C2 (en) 2017-09-11
JP2015509540A (en) 2015-03-30
NZ630251A (en) 2016-02-26
ES2681487T3 (en) 2018-09-13
JP2017039741A (en) 2017-02-23
US20160243119A1 (en) 2016-08-25
US20150374693A1 (en) 2015-12-31
IL252364B (en) 2018-03-29
MX2014010613A (en) 2014-09-18
ZA201406147B (en) 2015-12-23
WO2013134353A1 (en) 2013-09-12
SI2822939T1 (en) 2016-04-29
US9623026B2 (en) 2017-04-18
EA033124B1 (en) 2019-08-30
DK2822939T3 (en) 2016-03-14
US20150011561A1 (en) 2015-01-08
US9132128B2 (en) 2015-09-15
ME02460B (en) 2017-02-20
HK1226300A1 (en) 2017-09-29
EP3056494A1 (en) 2016-08-17
JP6016953B2 (en) 2016-10-26
IL252364A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
WO2013134353A8 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
SA518400547B1 (en) Pyrazolopyrimidine Derivatives as Kinase Inhibitor
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
HK1220355A1 (en) Mk2 inhibitors and uses thereof
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
AU2016214496B2 (en) 2-(HET)Aryl-substituted condensed bicyclic Heterocycle Derivatives as pest control agents
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
HK1246286A1 (en) Lrrk2 inhibitors and methods of making and using the same
WO2014100764A3 (en) Methods of inhibiting prmt5
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
HK1223093A1 (en) Fungicidal compositions
MY199894A (en) Prmt5 inhibitors and uses thereof
HK1217492A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
AU2015292632B2 (en) Aldosterone synthase inhibitors
WO2015197534A3 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
MX2014001510A (en) Anthranilamide compounds and their use as pesticides.
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
MX2015013414A (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors.
WO2013155465A8 (en) Substituted xanthine derivatives
WO2012154879A3 (en) Autophagy inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13710258

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 234239

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2865420

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014561069

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/010613

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2014002353

Country of ref document: CL

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013229995

Country of ref document: AU

Date of ref document: 20130306

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013710258

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147027590

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201491641

Country of ref document: EA

Ref document number: A201410832

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014021990

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2016/0238

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112014021990

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140905